Corient Private Wealth LLC Grows Holdings in Grifols, S.A. (NASDAQ:GRFS)

Corient Private Wealth LLC boosted its holdings in shares of Grifols, S.A. (NASDAQ:GRFS) by 11.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 50,883 shares of the biotechnology company’s stock after purchasing an additional 5,040 shares during the period. Corient Private Wealth LLC’s holdings in Grifols were worth $379,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. JPMorgan Chase & Co. lifted its stake in shares of Grifols by 144.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,002,511 shares of the biotechnology company’s stock worth $17,782,000 after acquiring an additional 1,181,959 shares during the period. Helikon Investments Ltd purchased a new position in Grifols during the fourth quarter worth about $580,000. Stifel Financial Corp acquired a new stake in Grifols in the third quarter valued at about $1,043,000. GAMMA Investing LLC boosted its holdings in Grifols by 44.5% in the 4th quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 1,527 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in Grifols during the 3rd quarter worth approximately $363,000.

Grifols Stock Performance

NASDAQ:GRFS opened at $7.27 on Monday. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. Grifols, S.A. has a fifty-two week low of $5.79 and a fifty-two week high of $9.96. The firm’s fifty day simple moving average is $7.56 and its 200-day simple moving average is $8.04. The stock has a market cap of $5.00 billion, a PE ratio of 6.21 and a beta of 0.35.

Analyst Ratings Changes

Separately, Morgan Stanley started coverage on Grifols in a research note on Wednesday, February 12th. They issued an “overweight” rating on the stock.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.